EPCAM and cancer: The high Ep-ICD expression observed in normal prostate tissues in our study may be attributed to the use of domain specific antibody for Ep-ICD while the other studies used antibodies against the external domain of the full length EpCAM protein or it might be attributed to the selection of normal tissues that included cases which had a negative biopsy and continued to have negative biopsy for at least 5 years and not the adjacent benign prostate tissues obtained from cancer patients.